 Shares of SIGA Technologies NASDAQ: SIGA closed lower by more than 20 following the release of a Food and Drug Administration FDA update. That update stated that SIGAs TPOXX, or tecovirimat, antiviral medication has not yet demonstrated any efficacy against monkeypox. 